ABC Arbitrage SA Has $532,000 Stock Holdings in Fresenius Medical Care AG & Co. KGaA $FMS

ABC Arbitrage SA trimmed its position in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 91.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,211 shares of the company’s stock after selling 209,164 shares during the period. ABC Arbitrage SA’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $532,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Hantz Financial Services Inc. grew its stake in Fresenius Medical Care AG & Co. KGaA by 220.9% in the third quarter. Hantz Financial Services Inc. now owns 6,671 shares of the company’s stock valued at $176,000 after acquiring an additional 4,592 shares during the period. Searle & CO. grew its position in Fresenius Medical Care AG & Co. KGaA by 246.6% in the 3rd quarter. Searle & CO. now owns 80,725 shares of the company’s stock valued at $2,125,000 after purchasing an additional 57,437 shares during the period. DMC Group LLC bought a new stake in Fresenius Medical Care AG & Co. KGaA during the 3rd quarter valued at $206,000. Evergreen Capital Management LLC raised its holdings in Fresenius Medical Care AG & Co. KGaA by 36.9% during the third quarter. Evergreen Capital Management LLC now owns 11,158 shares of the company’s stock worth $294,000 after buying an additional 3,007 shares during the last quarter. Finally, Forum Financial Management LP raised its holdings in Fresenius Medical Care AG & Co. KGaA by 51.0% during the third quarter. Forum Financial Management LP now owns 13,510 shares of the company’s stock worth $356,000 after buying an additional 4,564 shares during the last quarter. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.2%

NYSE FMS opened at $24.06 on Thursday. The stock has a market capitalization of $13.95 billion, a price-to-earnings ratio of 17.56, a PEG ratio of 0.76 and a beta of 0.90. Fresenius Medical Care AG & Co. KGaA has a one year low of $20.94 and a one year high of $30.46. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.36 and a quick ratio of 1.00. The business’s fifty day moving average is $23.16 and its 200-day moving average is $24.52.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Truist Financial set a $28.00 price objective on shares of Fresenius Medical Care AG & Co. KGaA in a report on Monday, January 5th. Bank of America cut shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research report on Wednesday, October 15th. UBS Group lowered Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a report on Wednesday, October 15th. Wall Street Zen raised Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. Finally, The Goldman Sachs Group cut Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 20th. Five analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $28.00.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.